

**American College of Radiology
ACR Appropriateness Criteria®**

Clinical Condition: Suspected Liver Metastases

Variant 1: Initial imaging test following detection of primary tumor.

Radiologic Procedure	Rating	Comments	<u>RRL*</u>
CT abdomen with contrast	8	Images are acquired during PVP. HAP imaging is useful for patients with a hypervascular primary tumor such as (but not limited to) renal cell, pancreatic islet cell, and thyroid carcinoma; carcinoid and other neuroendocrine tumors; and melanoma.	Med
MRI abdomen with contrast	7	Dynamic gadolinium-chelate-enhanced imaging is used most commonly. Delayed imaging after SPIO or gadolinium-BOPTA-enhanced imaging can be useful for staging patients with liver metastases. See statement regarding contrast in text under "Anticipated Exceptions."	None
FDG-PET whole body	6		High
CT abdomen without contrast	4		Med
MRI abdomen without contrast	4		None
US abdomen with or without Doppler	4		None
CT arterial portography liver	2		Med
CTA abdomen	2		Med
In-111 somatostatin receptor scintigraphy	2	May be useful in patients with neuroendocrine tumors.	High
<u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate			*Relative Radiation Level

Clinical Condition:

Suspected Liver Metastases

Variant 2:

Surveillance following treatment of primary tumor.

Radiologic Procedure	Rating	Comments	RRL*
CT abdomen with contrast	8	Images are acquired during PVP. HAP imaging is useful for patients with a hypervascular primary tumor such as (but not limited to) renal cell, pancreatic islet cell, and thyroid carcinoma; carcinoid and other neuroendocrine tumors; and melanoma.	Med
MRI abdomen with contrast	7	Dynamic gadolinium-chelate-enhanced imaging is used most commonly. Delayed imaging after SPIO or gadolinium-BOPTA-enhanced imaging can be useful for staging patients with liver metastases. See statement regarding contrast in text under "Anticipated Exceptions."	None
FDG-PET whole body	6		High
CT abdomen without contrast	4		Med
MRI abdomen without contrast	4		None
US abdomen with or without Doppler	4		None
In-111 somatostatin receptor scintigraphy	4	May be useful in patients with neuroendocrine tumors.	High
CT arterial portography liver	2		Med
CTA abdomen	2		Med
Rating Scale: 1=Least appropriate, 9=Most appropriate			*Relative Radiation Level

Clinical Condition:**Suspected Liver Metastases****Variant 3:****Abnormal surveillance US, CT, or MRI, in PVP: high suspicion of malignancy.**

Radiologic Procedure	Rating	Comments	<u>RRL*</u>
Percutaneous biopsy liver	8		NS
CT abdomen with contrast	8	Images are acquired during PVP. HAP imaging is useful for patients with a hypervascular primary tumor such as (but not limited to) renal cell, pancreatic islet cell, and thyroid carcinoma; carcinoid and other neuroendocrine tumors; and melanoma.	Med
MRI abdomen with contrast	8	Dynamic gadolinium-chelate-enhanced imaging is used most commonly. Delayed imaging after SPIO or gadolinium-BOPTA-enhanced imaging can be useful for staging patients with liver metastases. See statement regarding contrast in text under "Anticipated Exceptions."	None
FDG-PET whole body	8		High
MRI abdomen without contrast	4		None
US abdomen with or without Doppler	4		None
US abdomen intraoperative/laparoscopic	4		None
In-111 somatostatin receptor scintigraphy	3	May be useful in patients with neuroendocrine tumors.	High
CT arterial portography liver	3		Med
CTA abdomen	3		Med
CT abdomen without contrast	2		Med
<u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate			*Relative Radiation Level

Clinical Condition:**Suspected Liver Metastases****Variant 4:****Abnormal surveillance US, CT, or MRI in PVP: high suspicion of benignancy.**

Radiologic Procedure	Rating	Comments	<u>RRL*</u>
MRI abdomen with contrast	8	Dynamic gadolinium-chelate-enhanced imaging is used most commonly. Delayed imaging after SPIO or gadolinium-BOPTA-enhanced imaging can be useful for staging patients with liver metastases. See statement regarding contrast in text under "Anticipated Exceptions."	None
CT abdomen with contrast	8	Images are acquired during PVP. HAP imaging is useful for patients with a hypervascular primary tumor such as (but not limited to) renal cell, pancreatic islet cell, and thyroid carcinoma; carcinoid and other neuroendocrine tumors; and melanoma.	Med
MRI abdomen without contrast	5		None
Percutaneous biopsy liver	4		NS
US abdomen with or without Doppler	4		None
In-111 somatostatin receptor scintigraphy	3	May be useful in patients with neuroendocrine tumors.	High
CT arterial portography liver	3		Med
CTA abdomen	3		Med
US abdomen intraoperative/laparoscopic	3		None
FDG-PET whole body	2		High
CT abdomen without contrast	2		Med
<u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate			*Relative Radiation Level

SUSPECTED LIVER METASTASES

Expert Panel on Gastrointestinal Imaging:
Jay P. Heiken, MD¹; Robert L. Bree, MD, MHSA²;
Max Paul Rosen, MD, MPH³; W. Dennis Foley, MD⁴;
Spencer B. Gay, MD⁵; Thomas H. Grant DO⁶;
James E. Huprich, MD⁷; Tasneem Lalani, MD⁸;
Frank H. Miller, MD⁹; Gary S. Sudakoff, MD¹⁰;
Frederick L. Greene, MD¹¹; Don C. Rockey, MD.¹²

Summary of Literature Review

In the United States, metastatic disease is the most common cause of malignancy in the liver and is 20 to 50 times more common than primary liver cancer. The colon, stomach, pancreas, and breast are the most common primary sites. The appearance of a new lesion in the liver in a patient with a history of cancer strongly suggests hepatic metastasis. On the other hand, most small (1-1.5 cm) liver lesions, even in patients with known malignancy, are not malignant, especially if there are fewer than five lesions [1,2]. In most series, about one-third of patients who die with a malignancy have liver involvement.

The liver is susceptible to metastatic disease primarily due to the nature of the endothelial lining. The dual blood supply to the liver has an effect on the vascularity of liver metastases, with those supplied by the hepatic arterial system being more vascular than those supplied by the portal venous system. Most gastrointestinal cancer is spread through the portal venous system, whereas other tumors are spread through the hepatic arterial system [3]. Numerous imaging methods are available for detecting intrahepatic metastatic disease before, during, and after definitive therapy for the primary lesion. The usefulness of various imaging tests can vary significantly across institutions because of local radiological expertise, availability of equipment or personnel, and the wishes and biases of treating physicians and radiologists.

This document will review the broad variety of available imaging tests so that each can be rated by the consensus panel, realizing that many published scientific studies do

not compare all imaging tests at the current state of the art [4,5].

Ultrasound

Ultrasound (US) is the most available technique for liver imaging worldwide, and in many countries is the major imaging test used to search for liver metastases. In the United States, the relative availability of computed tomography (CT) and magnetic resonance imaging (MRI), limited physician involvement in the performance of US, and the lack of availability of US contrast agents contribute to a lesser role for US diagnosis. In the United States pretreatment and post-treatment screening for metastases is performed infrequently with US. Comparative studies demonstrate that unenhanced grey-scale US has high specificity but lower sensitivity than CT and MRI [4-6]. With US, metastases can be hypoechoic, hyperechoic, cystic, or diffuse. Doppler may be useful, particularly in vascular lesions such as neuroendocrine tumors, sarcomas, and lymphomas.

Intraoperative/Laparoscopic Ultrasound

Intraoperative ultrasound (IOUS) is the most accurate imaging technique for detecting liver metastases at the time of primary tumor resection or resection of previously identified hepatic metastases. It is complementary to surgical inspection and palpation. Additionally, IOUS can be important for localization of tumors for ablative techniques or to guide intraoperative biopsy or surgical resection [4,5,7,8].

Laparoscopic US (LUS), an alternative to open IOUS, has shown promising results. In one study of 55 patients with primary and secondary liver neoplasms who underwent LUS as part of a tumor ablation procedure, LUS demonstrated all 201 liver tumors shown by triphasic CT and an additional 21 lesions not shown by CT [9].

Computed Tomography

CT is particularly suited for the evaluation of metastatic disease, because the liver and potential extrahepatic sites of tumor spread can be evaluated during the same examination. Multidetector helical CT (MDCT) is the preferred examination in the United States for surveillance for metastatic disease after treatment of the primary neoplasm. Because most hepatic metastases are relatively hypovascular compared with normal liver parenchyma, the lesions are hypoattenuating when imaged during the peak of hepatic parenchymal enhancement (portal venous phase). In general, therefore, imaging during the portal venous phase of hepatic enhancement is adequate to detect most hepatic lesions in most patients [10-12].

Hypervascular lesions are less common, and tumors in this group include metastases from renal cell carcinoma, carcinoid, islet cell carcinoma, thyroid carcinoma, melanoma, and neuroendocrine tumors. In a large series of patients, small (<2 cm) hypervascular lesions were seen better in the arterial phase than in the portal venous

¹Principal Author, Mallinckrodt Institute of Radiology, Saint Louis, Missouri.

²Panel Chair, University of Washington, Seattle, Washington.

³Panel Vice-Chair, University of Pennsylvania, Philadelphia, Pennsylvania.

⁴Froedtert Hospital East, Milwaukee, Wisconsin.

⁵University of Virginia Health Science Center, Charlottesville, Virginia.

⁶Northwestern University Feinberg School of Medicine/NMH, Chicago, Illinois.

⁷Mayo Clinic, Rochester, Minnesota.

⁸Inland Imaging Associates, Seattle, Washington.

⁹Northwestern University Feinberg School of Medicine/NMH, Chicago, Illinois.

¹⁰Froedtert Hospital, Milwaukee, Wisconsin.

¹¹Carolinas Medical Center, Charlotte, North Carolina, American College of Surgeons.

¹²University of Texas, Southwestern Medical Center, Dallas, Texas, American Gastroenterological Association.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply society endorsement of the final document.

Reprint requests to: Department of Quality & Safety, American College of Radiology, 1891 Preston White Drive, Reston, VA 20191-4397.

phase [10]. With the widespread use of multidetector-row scanners, arterial phase scanning can be routine. Although metastases from breast carcinoma are sometimes hypervascular, two studies showed that arterial phase imaging was not necessary in this group [10,12]. Hypervascular lesions may be isoattenuating to liver during the portal venous phase of hepatic enhancement. With helical CT, both arterial and portal venous phase imaging is recommended for patients with hypervascular primary tumors. If helical CT is not available, a noncontrast scan can also be useful [13].

CT arterial portography is no longer used extensively, as it is an invasive angiographic technique that often yields confusing artifacts that decrease accuracy [4-6,13]. Newer arterial mapping techniques using MRI and CT angiography have largely replaced standard angiographic techniques for preoperative staging.

Magnetic Resonance Imaging

With MRI, most hepatic metastases are hypointense to normal liver on T1-weighted images and hyperintense to liver on T2-weighted images. Morphologic, signal intensity, and contrast enhancement features have been shown to be useful in distinguishing metastatic lesions from common benign lesions such as hemangiomas and cysts.

Contrast-enhanced imaging is an important part of the hepatic MRI examination for detection of metastases and is particularly useful in characterizing hepatic lesions that are identified. Gadolinium chelates, which are the most widely used MR contrast agents, are most useful when used with dynamic T1-weighted gradient echo sequences. Gadolinium-enhanced MRI and dynamic contrast-enhanced CT are comparable in their ability to identify patients with hepatic metastases. Most comparative studies, however, have shown MRI to be somewhat more sensitive than contrast-enhanced CT for detecting individual hepatic metastases [14-16], although comparative studies using state-of-the-art MDCT scanners are lacking. MRI using superparamagnetic iron oxide (SPIO) contrast agents, which are taken up selectively by the reticuloendothelial system, has been shown to be more sensitive than unenhanced MRI and equal to or more sensitive than gadolinium-enhanced MRI [17,18]. In one study SPIO-enhanced MRI also was more sensitive than 16-row MDCT for detecting liver metastases [19]. Delayed phase imaging during gadobenate dimeglumine (GD-BOPTA)-enhanced MRI [17] and mangafodipir trisodium (Mn-DPDP)-enhanced MRI [20,21] have been shown to be equivalent to SPIO-enhanced MRI for detecting liver metastases, but mangafodipir currently is not available in the United States.

Nuclear Imaging

Positron emission tomography (PET) has become more widely used in detecting metastatic disease. Two meta-analyses comparing CT, MRI, and 18F fluorodeoxyglucose (FDG) PET in patients with cancers of the gastrointestinal tract concluded that FDG-PET is

the most sensitive imaging test for distinguishing hepatic metastases from colorectal cancer [22,23]. In addition, several studies have demonstrated that the addition of FDG-PET to a conventional staging evaluation in colorectal cancer patients with potentially resectable liver metastases results in a change in management of 20%-32%, mainly due to detection of unknown extrahepatic disease. PET also has been shown to be accurate in distinguishing benign from malignant liver tumors. A limitation of FDG-PET, however, is that it may fail to demonstrate small (<1 cm) liver metastases [24-27]. In addition, the sensitivity of FDG-PET for demonstrating hepatic metastases from colorectal cancer is reduced in patients who have undergone recent chemotherapy [28]. For staging and restaging patients with colorectal liver metastases, integration of CT and FDG-PET data, either by fusion or by integrated PET-CT imaging, enables better management guidance than with either technique alone.

Traditional reticulo-endothelial radionuclide imaging is no longer used for detecting liver metastases. Somatostatin receptor scintigraphy is capable of demonstrating hepatic metastases from endocrine tumors but is not as sensitive as CT and MRI [29].

Summary

Many radiologic techniques are available for preoperative detection of liver metastases and postoperative surveillance. Some of the less widely used screening techniques can be useful when there is a need for specific problem solving. Rapid technological and clinical advances in equipment, contrast agents, and radioisotopes make direct comparison of the various techniques difficult. In addition, local custom and equipment availability within communities or medical centers can be expected to lead to a variety of indications and applications in detecting hepatic metastatic disease.

Anticipated Exceptions

Nephrogenic systemic fibrosis (NSF) is a disorder with a scleroderma-like presentation and a spectrum of manifestations that can range from limited clinical sequelae to fatality. It appears to be related to both underlying severe renal dysfunction and the administration of gadolinium-based contrast agents. It has occurred primarily in patients on dialysis, rarely in patients with very limited glomerular filtration rate (GFR) (ie, <30 mL/min/1.73m²), and almost never in other patients. There is growing literature regarding NSF. Although some controversy and lack of clarity remain, there is a consensus that it is advisable to avoid all gadolinium-based contrast agents in dialysis-dependent patients unless the possible benefits clearly outweigh the risk, and to limit the type and amount in patients with estimated GFR rates <30 mL/min/1.73m². For more information, please see the [ACR Manual on Contrast Media](#) [30].

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when

selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document.

Relative Radiation Level Designations	
Relative Radiation Level*	Effective Dose Estimate Range
None	0
Minimal	< 0.1 mSv
Low	0.1-1 mSv
Medium	1-10 mSv
High	10-100 mSv
*The RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, the region of the body exposed to ionizing radiation, the imaging guidance that is used, etc). The RRLs for these examinations are designated as NS (not specified).	

Supporting Document(s)

- [ACR Appropriateness Criteria® Overview](#)
- Evidence table under review

References

- Jones EC, Chezmar JL, Nelson RC, Bernardino ME. The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT. *AJR* 1992; 158(3):535-539.
- Schwartz LH, Gandras EJ, Colangelo SM, Ercolani MC, Panicek DM. Prevalence and importance of small hepatic lesions found at CT in patients with cancer. *Radiology* 1999; 210(1):71-74.
- Baker ME, Pelley R. Hepatic metastases: basic principles and implications for radiologists. *Radiology* 1995; 197(2):329-337.
- Kruskal JB, Kane RA. Imaging of primary and metastatic liver tumors. *Surg Oncol Clin N Am* 1996; 5(2):231-260.
- Mahfouz AE, Hamm B, Mathieu D. Imaging of metastases to the liver. *Eur Radiol* 1996; 6(5):607-614.
- Nies C, Leppek R, Sitter H, et al. Prospective evaluation of different diagnostic techniques for the detection of liver metastases at the time of primary resection of colorectal carcinoma. *Eur J Surg* 1996; 162(10):811-816.
- Rydzewski B, Dehdashti F, Gordon BA, Teefey SA, Strasberg SM, Siegel BA. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. *AJR* 2002; 178(2):353-358.
- Ward J, Naik KS, Guthrie JA, Wilson D, Robinson PJ. Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. *Radiology* 1999; 210(2):459-466.
- Foroutani A, Garland AM, Berber E, et al. Laparoscopic ultrasound vs triphasic computed tomography for detecting liver tumors. *Arch Surg* 2000; 135(8):933-938.
- Frederick MG, Paulson EK, Nelson RC. Helical CT for detecting focal liver lesions in patients with breast carcinoma: comparison of noncontrast phase, hepatic arterial phase, and portal venous phase. *J Comput Assist Tomogr* 1997; 21(2):229-235.
- Miller FH, Butler RS, Hoff FL, Fitzgerald SW, Nemcek AA, Jr., Gore RM. Using triphasic helical CT to detect focal hepatic lesions in patients with neoplasms. *AJR* 1998; 171(3):643-649.
- Sheafor DH, Frederick MG, Paulson EK, Keogan MT, DeLong DM, Nelson RC. Comparison of unenhanced, hepatic arterial-dominant, and portal venous-dominant phase helical CT for the detection of liver metastases in women with breast carcinoma. *AJR* 1999; 172(4):961-968.
- Oliver JH, 3rd, Baron RL, Federle MP, Jones BC, Sheng R. Hypervascular liver metastases: do unenhanced and hepatic arterial phase CT images affect tumor detection? *Radiology* 1997; 205(3):709-715.
- de Lange EE, Mugler JP, 3rd, Gay SB, DeAngelis GA, Berr SS, Harris EK. Focal liver disease: comparison of breath-hold T1-weighted MP-GRE MR imaging and contrast-enhanced CT--lesion detection, localization, and characterization. *Radiology* 1996; 200(2):465-473.
- Rummeny EJ, Wernecke K, Saini S, et al. Comparison between high-field-strength MR imaging and CT for screening of hepatic metastases: a receiver operating characteristic analysis. *Radiology* 1992; 182(3):879-886.
- Semelka RC, Shoenut JP, Kroeker MA, et al. Focal liver disease: comparison of dynamic contrast-enhanced CT and T2-weighted fat-suppressed, FLASH, and dynamic gadolinium-enhanced MR imaging at 1.5 T. *Radiology* 1992; 184(3):687-694.
- Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. *Eur Radiol* 2005; 15(2):220-228.
- Ward J, Robinson PJ, Guthrie JA, et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. *Radiology* 2005; 237(1):170-180.
- Kim YK, Ko SW, Hwang SB, Kim CS, Yu HC. Detection and characterization of liver metastases: 16-slice multidetector computed tomography versus superparamagnetic iron oxide-enhanced magnetic resonance imaging. *Eur Radiol* 2006; 16(6):1337-1345.
- Choi JY, Kim MJ, Kim JH, et al. Detection of hepatic metastasis: manganese- and ferucarbotran-enhanced MR imaging. *Eur J Radiol* 2006; 60(1):84-90.
- Kim HJ, Kim KW, Byun JH, et al. Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients. *AJR* 2006; 186(4):1059-1066.
- Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. *Radiology* 2005; 237(1):123-131.
- Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. *Radiology* 2002; 224(3):748-756.
- Fong Y, Saldinger PF, Akhurst T, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. *Am J Surg* 1999; 178(4):282-287.
- Rohren EM, Paulson EK, Hagge R, et al. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. *Clin Nucl Med* 2002; 27(8):550-555.
- Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. *J Clin Oncol* 2002; 20(2):388-395.
- Sahani DV, Kalva SP, Fischman AJ, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. *AJR* 2005; 185(1):239-246.
- Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. *J Clin Oncol* 2005; 23(34):8713-8716.
- Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of

somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. *J Clin Oncol* 2005; 23(1):70-78.

30. American College of Radiology. *Manual on Contrast Media*. Available at: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.